Regeneron Pharmaceuticals (REGN) Total Current Liabilities (2009 - 2026)
Regeneron Pharmaceuticals (REGN) posted quarterly Total Current Liabilities of $5.5 billion for Q2 2026, up 50.82% year-over-year from $3.7 billion in Q2 2025, and up 8.28% quarter-over-quarter from $5.1 billion in Q1 2026.
Regeneron Pharmaceuticals (REGN) Total Current Liabilities (2009 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' Total Current Liabilities history runs 18 years deep, the most recent figure standing at $5.5 billion for Q2 2026.
- In Q2 2026, Total Current Liabilities rose 50.82% year-over-year to $5.5 billion; the TTM figure through Jun 2026 stood at $5.5 billion (up 50.82% YoY), while the FY2025 annual figure was $4.4 billion, up 10.75% from the prior year.
- Total Current Liabilities for Q2 2026 stood at $5.5 billion, up from $5.1 billion in the prior quarter.
- The five-year high for Total Current Liabilities was $5.5 billion in Q2 2026, with the low at $2.9 billion in Q3 2022.
- The 5-year median for Total Current Liabilities is $3.6 billion (2024), against an average of $3.7 billion.
- The sharpest annual moves came in 2022 and 2026: Total Current Liabilities decreased 22.49% in 2022, then surged 50.82% in 2026.
- Regeneron Pharmaceuticals' Total Current Liabilities stood at $3.1 billion in 2022, then climbed by 8.98% to $3.4 billion in 2023, then gained by 15.22% to $3.9 billion in 2024, then grew by 10.75% to $4.4 billion in 2025, then increased by 26.6% to $5.5 billion in 2026.
- Business Quant data shows REGN's Total Current Liabilities at $5.5 billion in Q2 2026, $5.1 billion in Q1 2026, and $4.4 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 283.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.53 Bn |
| Mar 31, 2026 | 5.11 Bn |
| Dec 31, 2025 | 4.37 Bn |
| Sep 30, 2025 | 4.43 Bn |
| Jun 30, 2025 | 3.67 Bn |
| Mar 31, 2025 | 3.57 Bn |
| Dec 31, 2024 | 3.94 Bn |
| Sep 30, 2024 | 3.66 Bn |
| Jun 30, 2024 | 3.51 Bn |
| Mar 31, 2024 | 3.58 Bn |
| Dec 31, 2023 | 3.42 Bn |
| Sep 30, 2023 | 3.60 Bn |
| Jun 30, 2023 | 3.10 Bn |
| Mar 31, 2023 | 3.10 Bn |
| Dec 31, 2022 | 3.14 Bn |
| Sep 30, 2022 | 2.88 Bn |
| Jun 30, 2022 | 3.03 Bn |
| Mar 31, 2022 | 3.01 Bn |
| Dec 31, 2021 | 3.93 Bn |
| Sep 30, 2021 | 3.71 Bn |